Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy

References

• Siegel R, Miller K, Fuchs H, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Perou C, Sørlie T, Eisen M, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Leon-Ferre R, Hieken T, Boughey J. The landmark series: neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer. Ann Surg Oncol. 2021;28(4):2111–2119. doi:10.1245/s10434-020-09480-9
   PubMed Web of Science ®Google Scholar
• Yee D, DeMichele A, Yau C, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncology. 2020;6(9):1355–1362. doi:10.1001/jamaoncol.2020.2535
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/s0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im Y, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, Phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. doi:10.1016/s1470-2045(16)00163-7
   PubMed Web of Science ®Google Scholar
• Caudle A, Gonzalez-Angulo A, Hunt K, et al. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011;18(4):932–938. doi:10.1245/s10434-010-1390-8
   PubMed Web of Science ®Google Scholar
• Koklesova L, Liskova A, Samec M, et al. Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine. EPMA J. 2020;11(2):261–287. doi:10.1007/s13167-020-00210-5
   PubMed Web of Science ®Google Scholar
• Crigna A, Samec M, Koklesova L, et al. Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? EPMA J. 2020;11(4):603–627. doi:10.1007/s13167-020-00226-x
   PubMed Web of Science ®Google Scholar
• Mazurakova A, Koklesova L, Samec M, et al. Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. EPMA J. 2022;13(2):315–334. doi:10.1007/s13167-022-00277-2
   PubMed Web of Science ®Google Scholar
• Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11(11):792–804. doi:10.1038/nrc3139
   PubMed Web of Science ®Google Scholar
• Jamal A, Swarnalatha M, Sultana S, Joshi P, Panda S, Kumar V. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2. Cell Cycle. 2015;14(16):2688–2700. doi:10.1080/15384101.2015.1056946
   PubMed Web of Science ®Google Scholar
• Kim H, Frederick D, Levesque M, et al. Downregulation of the ubiquitin ligase RNF125 underlies resistance of melanoma cells to BRAF inhibitors via JAK1 deregulation. Cell Rep. 2015;11(9):1458–1473. doi:10.1016/j.celrep.2015.04.049
   PubMed Web of Science ®Google Scholar
• Koepp D, Schaefer L, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001;294(5540):173–177. doi:10.1126/science.1065203
   PubMed Web of Science ®Google Scholar
• Ozato K, Shin D, Chang T, Morse H. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008;8(11):849–860. doi:10.1038/nri2413
   PubMed Web of Science ®Google Scholar
• Napolitano L, Meroni G. TRIM family: pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life. 2012;64(1):64–71. doi:10.1002/iub.580
   PubMed Web of Science ®Google Scholar
• Zhang W, Cui Q, Qu W, Ding X, Jiang D, Liu H. TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma. Oncol Rep. 2018;40(1):206–216. doi:10.3892/or.2018.6426
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang X, Cai J, et al. Downregulation of TRIM58 expression is associated with a poor patient outcome and enhances colorectal cancer cell invasion. Oncol Rep. 2018;40(3):1251–1260. doi:10.3892/or.2018.6525
   PubMed Web of Science ®Google Scholar
• Liu X, Long Z, Cai H, Yu S, Wu J. TRIM58 suppresses the tumor growth in gastric cancer by inactivation of β-catenin signaling via ubiquitination. Cancer Biol Ther. 2020;21(3):203–212. doi:10.1080/15384047.2019.1679554
   PubMed Web of Science ®Google Scholar
• Du X, Wang J, Zhang D, et al. viaAUF1 Promotes Proliferation and Invasion of Thyroid Cancer Downregulation of ZBTB2 and Subsequent TRIM58. Front Oncol. 2021;11:681736. doi:10.3389/fonc.2021.681736
   PubMed Web of Science ®Google Scholar
• Gan Y, Cao C, Li A, et al. TRIM58Silencing of the gene by aberrant promoter methylation is associated with a poor patient outcome and promotes cell proliferation and migration in clear cell renal cell carcinoma. Front Mol Biosci. 2021;8:655126. doi:10.3389/fmolb.2021.655126
   PubMed Web of Science ®Google Scholar
• Wang J, Yang F, Zhuang J, Huo Q, Li J, Xie N. TRIM58 inactivates p53/p21 to promote chemoresistance via ubiquitination of DDX3 in breast cancer. Int J Biochem Cell Biol. 2022;143:106140. doi:10.1016/j.biocel.2021.106140
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795. doi:10.1200/JCO.2009.25.6529
   PubMed Web of Science ®Google Scholar
• Wolff A, Hammond M, Hicks D, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–256. doi:10.5858/arpa.2013-0953-SA
   PubMed Web of Science ®Google Scholar
• Glazyrin A, Shen X, Blanc V, Eliason JF. Direct detection of herceptin/trastuzumab binding on breast tissue sections. J Histochem Cytochem. 2007;55(1):25–33. doi:10.1369/jhc.6A7017.2006
   PubMed Web of Science ®Google Scholar
• Lánczky A, Győrffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23(7):e27633. doi:10.2196/27633
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman B, Lempicki R. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman B, Lempicki R. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi:10.1093/nar/gkn923
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable A, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Weigelt B, Peterse JL, Van ‘t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602. doi:10.1038/nrc1670
   PubMed Web of Science ®Google Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–458. doi:10.1038/nrc1098
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol. 2010;7(6):348–353. doi:10.1038/nrclinonc.2010.39
   PubMed Web of Science ®Google Scholar
• Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol. 2011;29(19):2619–2627. doi:10.1200/JCO.2010.29.5907
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang X, Fan L, Shao Z. Breast cancer-specific mortality in small-sized tumor with stage IV Breast cancer: a population-based study. Oncologist. 2021;26(2):e241–e250. doi:10.1002/onco.13567
   PubMed Web of Science ®Google Scholar
• Yu KD, Jiang YZ, Chen S, et al. Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clinic Proceedings. 2012;87(12):1171–1180. doi:10.1016/j.mayocp.2012.07.023
   PubMed Web of Science ®Google Scholar
• Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42(4):297–311. doi:10.1016/j.tibs.2017.01.002
   PubMed Web of Science ®Google Scholar
• Azuma K, Ikeda K, Suzuki T, Aogi K, Horie-Inoue K, Inoue S. TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 2021;118(35). doi:10.1073/pnas.2100784118
   PubMed Web of Science ®Google Scholar
• Xing L, Tang X, Wu K, Huang X, Yi Y, Huan J. TRIM27 functions as a novel oncogene in non-triple-negative breast cancer by blocking cellular senescence through p21 ubiquitination. Mol Ther Nucleic Acids. 2020;22:910–923. doi:10.1016/j.omtn.2020.10.012
   PubMedGoogle Scholar
• Ye R, AiErken N, Kuang X, et al. Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogenesis. 2021;10(9):60. doi:10.1038/s41389-021-00350-x
   PubMed Web of Science ®Google Scholar
• McFadyen M, McLeod H, Jackson F, Melvin W, Doehmer J, Murray G. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol. 2001;62(2):207–212. doi:10.1016/s0006-2952(01
   PubMed Web of Science ®Google Scholar
• Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007;7(5):362–365. doi:10.1038/sj.tpj.6500434
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin M, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010;102(6):1003–1009. doi:10.1038/sj.bjc.6605587
   PubMed Web of Science ®Google Scholar
• Luo B, Yan D, Yan H, Yuan J. Cytochrome P450: implications for human breast cancer. Oncol Lett. 2021;22(1):548. doi:10.3892/ol.2021.12809
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang W, Song Z, et al. MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma. J Thorac Oncol. 2018;13(10):e202–e204. doi:10.1016/j.jtho.2018.05.009
   PubMed Web of Science ®Google Scholar
• Yen M, Wu K, Liu Y, et al. Ubiquitin conjugating enzyme E2 H (UBE2H) is linked to poor outcomes and metastasis in lung adenocarcinoma. Biology. 2021;10(5):378. doi:10.3390/biology10050378
   PubMed Web of Science ®Google Scholar
• Masjedi S, Zwiebel L, Giorgio T. Olfactory receptor gene abundance in invasive breast carcinoma. Sci Rep. 2019;9(1):13736. doi:10.1038/s41598-019-50085-4
   PubMed Web of Science ®Google Scholar
• Xu M, Gong J. Prognostic signature, immune features, and therapeutic responses of a novel ubiquitination-related gene signature in lung adenocarcinoma. J Oncol. 2022;2022:2524649. doi:10.1155/2022/2524649
   PubMed Web of Science ®Google Scholar
• Han Y, Li Y. Comprehensive exploration of M2 macrophages and its related genes for predicting clinical outcomes and drug sensitivity in lung squamous cell carcinoma. J Oncol. 2022;2022:1163924. doi:10.1155/2022/1163924
   PubMed Web of Science ®Google Scholar